Clinical Study Results
The table below shows the adverse reactions that researchers thought were related to
the study drugs.
Adverse reactions
Durvalumab and
Durvalumab only tremelimumab Total
(Out of 32 (Out of 32 (Out of 64
participants) participants) participants)
Participants who had
31.3% (10) 34.4% (11) 32.8% (21)
related adverse reactions
What adverse reactions did the participants have?
The most common adverse reactions that the researchers thought were related to the
study drugs were tiredness, diarrhea, and low thyroid function.
These adverse reactions happened in 3 participants in either treatment group. There
were other adverse reactions, but they happened in fewer participants.
The table below shows these adverse reactions.
Most common adverse reactions
Durvalumab and
Durvalumab only tremelimumab Total
(Out of 32 (Out of 32 (Out of 64
participants) participants) participants)
Tiredness 9.4% (3) 12.5% (4) 10.9% (7)
Diarrhea 6.3% (2) 12.5% (4) 9.4% (6)
Low thyroid function 0.0% (0) 9.4% (3) 4.7% (3)
How has this study helped participants and researchers?
The results presented here are for a single study. These results helped researchers learn
about the safety of durvalumab and if it helps participants with pancreatic cancer.
Researchers look at the results of many studies to decide which treatments work best
and are safest. This summary shows only the main results from this 1 study. Other
studies may provide new information or different results.
Further clinical studies with durvalumab and tremelimumab in patients with metastatic
pancreatic cancer are not currently planned.
7